Pawelski S, Brodzki L M, Gepner-Woźniewska M
Institute of Haematology, Warsaw, Poland.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(1):71-4.
Low dose Ara-C (10-15 mg/m2) was administered subcutaneously in 1-5 courses of 14 to 21 days to 16 patients with acute nonlymphoblastic leukaemia, mostly in elderly persons and/or with pancytopenia in whom conventional chemotherapy was contraindicated or ineffective. 18 of the 26 patients were females and 8 males. The mean age was 54.9 years ranging from 31 to 81 years. Mean duration of treatment was 15.2 days. Five complete remissions and three partial remissions were obtained. The mean duration of complete remission was 4.7 months and the mean duration of partial remission was 6.7 months. Aggravation of cytopenia during the treatment and hypocellularity of bone marrow aspirates at the end of therapy suggest that low dose Ara-C exerts its main activity by suppression of leukaemic proliferation rather than by induction of differentiation in malignant cells. Our results show that low dose of Ara-C could be valuable alternative treatment in patients with contraindications or ineffectiveness of conventional intensive chemotherapy.
对16例急性非淋巴细胞白血病患者皮下注射小剂量阿糖胞苷（10 - 15mg/m²），疗程为14至21天，共1 - 5个疗程，这些患者大多为老年人和/或全血细胞减少症患者，传统化疗对其有禁忌或无效。26例患者中18例为女性，8例为男性。平均年龄为54.9岁，范围在31至81岁之间。平均治疗持续时间为15.2天。获得了5例完全缓解和3例部分缓解。完全缓解的平均持续时间为4.7个月，部分缓解的平均持续时间为6.7个月。治疗期间血细胞减少加重以及治疗结束时骨髓穿刺涂片细胞减少表明，小剂量阿糖胞苷主要通过抑制白血病细胞增殖发挥作用，而非诱导恶性细胞分化。我们的结果表明，对于传统强化化疗有禁忌或无效的患者，小剂量阿糖胞苷可能是一种有价值的替代治疗方法。
